Evidence map›Paper›PMID 33247624›Full record

ArticleESC heart failure2021

N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial.

Mahmoud U Sani, Albertino Damasceno, Beth A Davison, Gad Cotter, Bongani M Mayosi, Christopher Edwards, Feriel Azibani, Tasneem Adam, Gulnaze Arif, Neusa Jessen and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01822808 (A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01822808 phase3unknown statusnot on this map

A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction

TypeinterventionalSponsorUniversity of Cape TownRan2013 to 2016Enrolled500ConditionsAcute Heart Failure, Left Ventricular DysfunctionArmsHydralazine, Isosorbide Dinitrate
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Mahmoud U SaniDepartment of Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.ORCID 0000-0001-8946-129X
Albertino DamascenoEduardo Mondlane University, Maputo, Mozambique.
Beth A DavisonMomentum Research Inc., Durham, NC, USA.
Gad CotterMomentum Research Inc., Durham, NC, USA.
Bongani M MayosiDepartment of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
Christopher EdwardsMomentum Research Inc., Durham, NC, USA.
Feriel AzibaniHatter Institute for Cardiovascular Research in Africa & IDM, Inter Cape Heart Group South African Medical Research Council, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Tasneem AdamHatter Institute for Cardiovascular Research in Africa & IDM, Inter Cape Heart Group South African Medical Research Council, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Gulnaze ArifEduardo Mondlane University, Maputo, Mozambique.
Neusa JessenEduardo Mondlane University, Maputo, Mozambique.
Karen SliwaHatter Institute for Cardiovascular Research in Africa & IDM, Inter Cape Heart Group South African Medical Research Council, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Eduardo Mondlane University · MZSouth African Medical Research Council · ZAInserm · FRAminu Kano Teaching Hospital · NGMomentum Research · USUniversity of Cape Town · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe relationship between N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and galectin-3 and outcomes has not been studied in African patients with acute heart failure (AHF). The current analysis sought to describe the association between plasma levels of NT-pro-BNP and galectin-3 and cardiovascular (CV) death or heart failure (HF) hospitalization, as well as their associations with symptoms and echocardiography markers of left and right ventricular remodelling among AHF patientsv in sub-Saharan Africa. METHODS AND

resultsIn a subset of 80 patients with complete data in a study assessing the effects of hydralazine and nitrates in patients with AHF (BAHEF trial; NCT01822808), NT-pro-BNP and galectin-3 analyses were performed, and the association with various characteristics and outcome measures assessed. The mean age of the patients for whom the aforementioned biomarkers were measured was 52.6 years, with 52.5% women. Galectin-3 at baseline predicted changes (Week 24 to baseline) in left ventricular ejection fraction, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and tricuspid annular plane systolic excursion. Biomarkers and their changes were not associated with changes in 6 min walk test at 24 weeks. Baseline galectin-3 and change in NT-pro-BNP were associated with improvements in dyspnoea at 24 weeks. Nine patients had an HF readmission or died of CV causes through 24 weeks (11.6%). Both biomarkers at baseline predicted combined CV death or HF hospitalization through Week 24 (P-values = 0.0328 and 0.0001, respectively).

conclusionsIn a cohort of patients with AHF from sub-Saharan Africa, NT-pro-BNP and galectin-3 at baseline and their changes were associated with some changes in dyspnoea, echocardiographic remodelling, and CV death or HF hospitalization through Week 24. These tests have potential of being used for risk stratification of AHF patients in sub-Saharan Africa where resources are scarce.

Indexed as

Galectin 3Heart FailureBiomarkersFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisStroke VolumeVentricular Function, LeftBiomarkersGalectin 3Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Acute heart failureAfricaGalectin-3NT-pro-BNPOutcomes

Identifiers

PMID33247624
PMCPMC7835570
OpenAlexW3109075775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.